Comparing Avalo Therapeutics (AVTX) & Its Competitors

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Avalo Therapeutics to similar businesses based on the strength of its valuation, profitability, dividends, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Avalo Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avalo Therapeutics N/A -34.21% -29.84%
Avalo Therapeutics Competitors -12,516.26% -215.37% -31.41%

Volatility and Risk

Avalo Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Avalo Therapeutics’ rivals have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.

Earnings & Valuation

This table compares Avalo Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Avalo Therapeutics $60,000.00 -$78.26 million -2.68
Avalo Therapeutics Competitors $718.90 million $8.79 million -18.37

Avalo Therapeutics’ rivals have higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Avalo Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalo Therapeutics 1 2 11 0 2.71
Avalo Therapeutics Competitors 9926 15341 45743 1601 2.54

Avalo Therapeutics currently has a consensus price target of $36.82, suggesting a potential upside of 445.45%. As a group, “Biotechnology” companies have a potential upside of 110.47%. Given Avalo Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than its rivals.

Summary

Avalo Therapeutics beats its rivals on 8 of the 12 factors compared.

About Avalo Therapeutics

(Get Free Report)

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.